Use of the tumor necrosis factor-blockers for Crohn's disease

Table 16 Therapeutic gain of certolizumab Induction of response and remission (%)

Week	Response		TG (CER-PL)
	CER	PL
CRP < 10 mg/L
6	371	26	111
26	22	12	10
Overall population
6	352	27	81
26	232	16	71
Remission
6	17	22	-
6 + 26	10	14	-
Maintenance with CER
Week 26 clinical response	621	34	281
Overall group	631	36	271

¹Significant difference;

²The secondary failure rates for CRP were 72% at 26 wk (approximately 10% per month). Precise I study (Pegylated Antibody Fragment Evaluation in Crohn’s Disease: Safety and Efficacy I). PL: Placebo; CRP: C-reactive protein; CER: Certolizumab; TG: Therapeutic gain.